Jan. 12, 2021—Discovering the mechanism behind cell behavior that is a hallmark of type 2 diabetes, Vanderbilt researchers move closer to treatments for the disease, which affects 34 million Americans.
Vanderbilt Diabetes Center seeks pilot and feasibility proposals to study interaction of SARS-CoV-2, diabetes
Dec. 16, 2020—The Vanderbilt Diabetes Center, the NIH-funded Diabetes Research and Training Center, and the NIH-funded Center for Diabetes Translational Research seek pilot and feasibility proposals to study the interaction of SARS-CoV-2/COVID-19 and diabetes.
Dec. 10, 2020—COVID-19 has been linked to cases of new-onset diabetes, diabetes-related emergencies and a higher death rate among diabetes patients.
Nov. 17, 2020—A study group of more than 600,000 patients with type 2 diabetes, identified from electronic medical records in the PCORnet national research network, could be valuable for assessing the safety of type 2 diabetes drugs.
Nov. 3, 2020—Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity.
Oct. 5, 2020—Vanderbilt researchers have identified a signaling pathway that promotes kidney fibrosis in patients with diabetes — and that could be targeted with an existing approved medication.
Sep. 11, 2020—One in nine American adults has diabetes, and one in three has pre-diabetes. Prevention and early intervention can decrease the risk of complications down the road.
Aug. 19, 2020—Research by Vanderbilt history professor Arleen Tuchman on the cultural history of diabetes offers important lessons for other public health challenges, including COVID-19.
Jul. 9, 2020—Vanderbilt cell biologists are defining the factors that help beta cells in the pancreas stay healthy, secrete insulin and prevent diabetes initiation and progression.
Apr. 8, 2020—Variation in the levels of hormones called natriuretic peptides may contribute to racial differences in susceptibility to diabetes, suggesting that this hormone system may be a target for reducing risk of the disease.
Feb. 20, 2020—Post-transplantation diabetes mellitus (PTDM), a common complication of immunosuppressive drugs that are given to prevent transplant rejection, may be reversible and at least partially preventable, researchers at VUMC report.
Dec. 11, 2019—Shichun Bao, associate professor of medicine and the Diabetes Technology Program leader in the Division of Endocrinology at the Eskind Diabetes Clinic, shares information on the amazing technological advances in diabetes treatment and blood sugar management.